Dr. Lim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Unit 1354
Houston, TX 77030Phone+1 713-563-0744- Is this information wrong?
Summary
- She received her medical degree from Ewha Women's University College of Medicine and has practiced for 20 years. She specializes in breast cancer and hematologic oncology, and translational research, and is experienced in breast cancer, inflammatory breast cancer, metastatic diseases, triple-negative breast cancer, and drug development.
Education & Training
- Penn State Milton S Hershey Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
- Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2011
- Ewha Women's University College of MedicineClass of 2004
- Ewha Womans UniversityBachelor's, 1998 - 2000
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2014 - 2024
- PA State Medical License 2007 - 2014
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Multidisciplinary Teacher Award Breast Surgical Oncology Fellows, 2017
- Best Research Projects for Clinical Fellows PennState College of Medicine, 2014
- Lou-Dinon Teaching Award University of Pennsylvania Medical Students, 2011
- Join now to see all
Clinical Trials
- Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Start of enrollment: 2016 Aug 26
- Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Start of enrollment: 2017 Jan 26
- Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2018 Jan 29
- Join now to see all
Publications & Presentations
PubMed
- Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.Elena Oropeza, Sinem Seker, Sabrina Carrel, Aloran Mazumder, Daniel Lozano, Athena Jimenez, Sabrina N VandenHeuvel, Dillon A Noltensmeyer, Nindo B Punturi, Jonathan T ...> ;Science Advances. 2023 Jun 30
- 15 citationsA spatially resolved single-cell genomic atlas of the adult human breast.Tapsi Kumar, Kevin Nee, Runmin Wei, Siyuan He, Quy H Nguyen, Shanshan Bai, Kerrigan Blake, Maren Pein, Yanwen Gong, Emi Sei, Min Hu, Anna K Casasent, Aatish Thennavan,...> ;Nature. 2023 Aug 1
- 1 citationsPredictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospecti...Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M Rauch, Qingqing Ding, Bora Lim, Alastair M Thompson, Elizabeth A Mittendorf, Beatriz E Adrada, Senthil Damodaran, Kiran ...> ;Cancers. 2023 Jun 21
- Join now to see all
Journal Articles
- Rates of Immune Cell Infiltration in Patients with Triple-Negative Breast Cancer by Molecular SubtypeWendy A Woodward, Naoto T Ueno, Savitri Krishnamurthy, Bora Lim, PLoS One
- Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast CancerMichael C Stauder, Anthony Lucci, Wendy A Woodward, Bora Lim, Naoto T Ueno, ScienceDirect
- International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Con...Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M,..., J Cancer, 1/1/2018
- Join now to see all
Abstracts/Posters
- Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancerWang W, Matsuda N, Lim B, Krishnamurthy S, Song J, Shen Y, Wu J, Hu J, Woodward WA, Reuben JM, Lucci A, Tripathy D, Valero V, Ueno NT, AACR Annual Meeting, 1/1/2018
- Identification of molecular therapeutic targets that enhance the antitumor activity of neratinib in breast cancer cellsLim B, Lee J, Pearson T, Huey L, Hwang M, Choi K, Avogadri-Connors F, Cutler RE, Jr., Tripathy D, Ueno NT, AACR Annual Meeting, 1/1/2018
- E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cellsLee J, Lim B, Choi K, Pearson T, Paradiso L, Myers T, Tripathy D, Ueno NT, AACR Annual Meeting, 1/1/2018
- Join now to see all
Lectures
- Novel combination of AR inhibitor and CDK4/6 inhibitor in non-HR positive (Triple Negative) breast cancersBarcelona, Spain - 1/23/2018
- Clinical Updates, and New InitiativesHouston, TX - 1/20/2018
- New Upcoming Therapeutics in TNBCHouston, TX - 1/21/2017
- Join now to see all
Press Mentions
- Celcuity Using CELSignia Test to Select Breast Cancer Patients for Phase II Trial of Tabrecta, NerlynxMarch 17th, 2021
- CELC Inks Breast Cancer Trial Collaboration, CANF Soars on Deal with Ewopharma, MRUS on WatchMarch 17th, 2021
- 7 Things to Know About Menopause and Breast CancerOctober 8th, 2019
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: